RTP Mobile Logo

Saturday, November 4, 2017, Boston, MA - 8:00 AM – 4:00 PM (Eastern Time)

Year in Review — A Multitumor Regional Symposia Series Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers

Event Details

Saturday, November 4, 2017

Program Time:
8:00 AM – 4:00 PM (Eastern Time)

Westin Boston Waterfront
425 Summer Street
Boston, MA 02210
Hotel phone: (617) 532-4600

Meeting Room:
Harbor Ballroom – Conference Level

Hotel Accommodations:
Please see Location tab for additional details.

There is no registration fee for this event. Seating is limited to clinicians in practice. Preregistration is required.

Acute Leukemias

Hagop M Kantarjian, MD
Chairman and Professor, Leukemia Department
The University of Texas MD Anderson Cancer Center
Houston, Texas

Eytan Stein, MD
Hematologic Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York

Breast Cancer

Harold J Burstein, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Mark D Pegram, MD
Susy Yuan-Huey Hung Professor of Medicine
Director of the Breast Oncology Program
Co-Director, Translational Oncology Program
Associate Director for Clinical Research
Stanford Cancer Institute
Stanford University School of Medicine
Stanford, California

Gastrointestinal Cancers

Tanios Bekaii-Saab, MD
Mayo Clinic College of Medicine and Science
Co-Leader, GI Cancer Program
Mayo Clinic Cancer Center
Senior Associate Consultant
Mayo Clinic, Arizona
Scottsdale, Arizona

Johanna C Bendell, MD
Director, GI Oncology Research
Associate Director, Drug Development Unit
Sarah Cannon Research Institute
Nashville, Tennessee

Genitourinary Cancers

William K Oh, MD
Chief, Division of Hematology and
Medical Oncology
Professor of Medicine and Urology
Ezra M Greenspan, MD Professor
in Clinical Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
Associate Director of Clinical Research
The Tisch Cancer Institute
Mount Sinai Health System
New York, New York

Daniel P Petrylak, MD
Professor of Medicine
Director, Prostate and GU Medical Oncology
Co-Director, Signal Transduction Program
Yale Cancer Center
New Haven, Connecticut

Lung Cancer

Matthew Gubens, MD, MS
Associate Professor, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California

Roy S Herbst, MD, PhD
Ensign Professor of Medicine
Professor of Pharmacology
Chief of Medical Oncology
Director, Thoracic Oncology Research Program
Associate Director for Translational Research
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, Connecticut

Lecia V Sequist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Center for Thoracic Cancers
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Hodgkin and Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia

Stephen M Ansell, MD, PhD
Professor of Medicine
Division of Hematology
Mayo Clinic
Rochester, Minnesota

Steven M Horwitz, MD
Associate Attending
Lymphoma Service
Division of Hematologic Oncology
Memorial Sloan Kettering Cancer Center
New York, New York

Ann S LaCasce, MD, MMSc
Program Director, Fellowship in Hematology/Oncology
Associate Professor of Medicine, Harvard Medical School
Lymphoma Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Ovarian Cancer

Michael Birrer, MD, PhD
Director, UAB Comprehensive Cancer Center
University of Alabama at Birmingham
Birmingham, Alabama

Ursula A Matulonis, MD
Medical Director and Program Leader
Gynecologic Oncology Program
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Neil Love, MD
Research To Practice
Miami, Florida



Each module will include a moderated slide presentation reviewing key publications, presentations and ongoing trials in addition to a clinical decision-making track facilitated through the use of networked tablet technology. All events will take place from 8:00 AM to 4:00 PM (breakfast and lunch buffets to be provided).

MODULE 1: Genitourinary Cancers 8:05 AM – 8:55 AM

  • Research database supporting the recent FDA approvals of atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab in urothelial bladder cancer (UBC); patient selection for and use of these agents in clinical practice
  • Active and planned clinical trials of immune checkpoint inhibitors alone or in combination for early and advanced UBC
  • Results of clinical trials evaluating (neo)adjuvant anti-VEGF therapy for unfavorable/high-risk localized or locally advanced renal cell carcinoma (RCC)
  • Optimal selection of VEGF-directed therapy for newly diagnosed metastatic RCC (mRCC)
  • Current clinical role of nivolumab in advanced RCC; ongoing trials evaluating immune checkpoint inhibitors in RCC
  • Clinical experience with cabozantinib and current role in the management of advanced RCC; available data with first-line therapy
  • Integration of lenvatinib/everolimus into the care of patients with mRCC
  • Investigational approaches with enzalutamide, abiraterone and sipuleucel-T in patients with nonmetastatic castration-resistant prostate cancer (CRPC)
  • Available Phase III data with and potential clinical role of adding abiraterone/prednisone to standard hormonal therapy for patients with hormone-sensitive metastatic prostate cancer
  • Clinical and biologic factors affecting the sequence and selection of secondary hormonal therapy, immunotherapy and cytotoxic therapy for patients with metastatic CRPC (mCRPC)
  • Current indications for radium-223 chloride in clinical practice and rational combination strategies (eg, other bone-targeted or secondary hormonal therapy)
  • Incidence of somatic or germline mutations in BRCA1, BRCA2 or ATM in patients with mCRPC; ongoing evaluation of PARP inhibition as a therapeutic strategy

MODULE 2: Lung Cancer 8:55 AM – 10:10 AM

  • First-line treatment options for patients with EGFR mutation-positive disease; potential implications of the Phase III FLAURA trial results
  • Available efficacy and safety data with osimertinib; effectiveness in patients with CNS metastases
  • Selection of first-, second- and later-line therapy for patients with ALK- or ROS1-positive disease; implications of recent data sets and drug approvals
  • Recent FDA approval of dabrafenib/trametinib for patients with BRAF V600E tumor mutations
  • Potential treatment options for patients with other oncogenic mutations (eg, HER2, MET exon 14, RET, NTRK gene fusions)
  • Design, efficacy endpoints and available data from the PACIFIC trial evaluating the use of durvalumab as sequential therapy for patients with locally advanced disease after completion of definitive chemoradiation therapy
  • Available data with and patient selection for pembrolizumab with and without chemotherapy in individuals with newly diagnosed metastatic non-small cell lung cancer (NSCLC)
  • Ongoing trials of anti-PD-1/PD-L1 antibodies in combination with other immunotherapeutic, chemotherapeutic or targeted approaches
  • Selection of first-line therapy for patients with PD-L1-negative squamous NSCLC
  • Rational integration of ramucirumab into the management of nonsquamous and squamous NSCLC
  • Novel agents under evaluation in small cell lung cancer and malignant pleural mesothelioma

MODULE 3: Gastrointestinal Cancers 10:25 AM – 11:15 AM

  • Patient and disease characteristics guiding therapy for patients with metastatic colorectal cancer (mCRC), including primary tumor location and presence of potentially targetable genetic abnormalities (eg, BRAF, HER2)
  • FDA approval of pembrolizumab and nivolumab for patients with MSI-high or mismatch repair-deficient tumors; integration into current mCRC treatment algorithms
  • Rational incorporation of regorafenib and TAS-102 into the treatment algorithm for mCRC and early activity and safety data in treatment-refractory gastric cancer
  • Integration of ramucirumab into clinical algorithms for metastatic HER2-negative and HER2-positive gastric/gastroesophageal junction (GEJ) cancer
  • Ongoing evaluation and current off-protocol role, if any, of FOLFIRINOX or nanoparticle albumin-bound (nab) paclitaxel/gemcitabine for patients with pancreatic adenocarcinoma in the neoadjuvant and adjuvant settings
  • Optimal integration of nanoliposomal irinotecan (nal-IRI) into clinical practice
  • Recent FDA approval of pembrolizumab for PD-L1-positive recurrent or advanced gastric/GEJ adenocarcinoma after 2 or more lines of chemotherapy and, if appropriate, HER2-targeted therapy; ongoing trials of anti-PD-1/PD-L1 antibodies alone or in combination with other systemic or immunotherapeutic approaches
  • Implications for clinical practice of the recent FDA approvals of regorafenib and nivolumab for patients with hepatocellular carcinoma (HCC) previously treated with sorafenib
  • Emerging data comparing lenvatinib to sorafenib in patients with advanced, unresectable HCC
  • Clinical utility and optimal employment of long-acting somatostatin analogues for neuroendocrine tumors (NETs)
  • Current clinical role of everolimus for patients with locally advanced or metastatic, nonfunctional NET of lung or gastrointestinal (GI) origin
  • Recent FDA approval of telotristat ethyl for patients with carcinoid syndrome and findings from recent Phase III trials
  • Ongoing investigation of other novel agents and strategies in GI cancers (eg, napabucasin, PEGPH20)

MODULE 4: Acute Leukemias 11:15 AM – 12:05 PM

  • Evidence-based induction regimens and postinduction consolidation and/or maintenance therapy for younger/fit patients with acute myeloid leukemia (AML)
  • Optimal integration of CPX-351 into the treatment of newly diagnosed therapy-related AML or AML with myelodysplasia-related changes
  • Indications for the use of hypomethylating agents as induction and/or maintenance therapy in elderly patients or those with poor-risk AML
  • FDA approval of midostaurin for patients with newly diagnosed AML and a FLT3 mutation; patient selection and practical aspects related to its administration
  • Mechanisms of action and available research data with the recently FDA-approved IDH1/2 inhibitor enasidenib; ongoing evaluation of novel IDH1/2 (eg, ivosidenib [AG-120]) and FLT3 (eg, gilteritinib, quizartinib) inhibitors in AML
  • Recent FDA approval and current clinical role of gemtuzumab ozogamicin for CD33-positive AML
  • Other novel agents under evaluation in AML (eg, venetoclax, pracinostat, GMI-1271)
  • Selection and sequencing of therapy for patients with Philadelphia chromosome-positive and negative acute lymphoblastic leukemia (ALL)
  • FDA approval of CAR T-cell therapy for pediatric and young adult patients with ALL that is refractory or in second or later relapse; ongoing clinical investigation for older adult patients
  • Clinical experience with different preparations of asparaginase in young adult and adult patients with ALL
  • Patient selection for blinatumomab in ALL clinical practice
  • Available research data supporting the recent FDA approval of inotuzumab ozogamicin in relapsed/refractory (R/R) B-cell precursor ALL
  • Diagnostic considerations for acute promyelocytic leukemia (APL); investigational approaches for low/intermediate-risk disease; choice of induction regimen for patients with high-risk disease

MODULE 5: Ovarian Cancer 12:50 PM – 1:40 PM

  • Similarities and differences between available genetic testing platforms; role of extended panel testing/next-generation sequencing
  • Identification of “BRCA-like” and other genomic signatures (eg, homologous recombination deficiency) that may predict benefit from PARP inhibition
  • Optimal integration of niraparib, olaparib and rucaparib into current ovarian cancer (OC) treatment algorithms; ongoing evaluation of investigational PARP inhibitors
  • Clinical role of niraparib and olaparib as maintenance therapy; Phase III study results with maintenance rucaparib
  • Recognition and management of PARP inhibitor-related side effects (anemia, GI toxicity, pneumonitis, et cetera)
  • Patient selection for neoadjuvant systemic therapy; available data defining the optimal neoadjuvant regimen
  • Risks and benefits of intraperitoneal chemotherapy; indications for its use in clinical practice
  • Optimal integration of bevacizumab in combination with chemotherapy followed by maintenance bevacizumab into the treatment algorithm for patients with platinum-sensitive recurrent OC
  • Mechanism of action of, available efficacy data with and ongoing trials evaluating the role of mirvetuximab soravtansine
  • Available safety and efficacy data with and ongoing trials evaluating anti-PD-1/PD-L1 antibodies in patients with OC

MODULE 6: Hodgkin and Non-Hodgkin Lymphomas/
Chronic Lymphocytic Leukemia
1:40 PM – 2:55 PM

  • Selection of up-front treatment for chronic lymphocytic leukemia (CLL) in younger and older patients with normal- and high-risk cytogenetics
  • Emerging research evidence with and nonprotocol role, if any, of maintenance therapy in CLL
  • Practical integration of venetoclax into clinical algorithms; emerging data with use beyond del(17p) disease
  • Novel strategies under investigation in CLL (eg, acalabrutinib, ublituximab, anti-PD-1/PD-L1 antibodies)
  • FDA approval of subcutaneous rituximab and potential clinical utility
  • Efficacy and safety of obinutuzumab-based induction and maintenance therapy for patients with previously untreated follicular lymphoma (FL)
  • Available data with and ongoing evaluation of the “R squared” regimen in FL
  • Recent FDA accelerated approval of copanlisib for relapsed FL and ongoing investigation of novel agents in FL (eg, ibrutinib, venetoclax, denintuzumab mafodotin)
  • Available and emerging research information with novel agents as a component of induction and/or post-transplant maintenance therapy in mantle cell lymphoma and treatment options for patients with R/R disease
  • Preliminary outcomes with brentuximab vedotin (BV) as a component of first-line therapy for patients with Hodgkin lymphoma (HL); practical considerations with the use of BV as a bridge to or as consolidation after transplant
  • FDA approvals of nivolumab and pembrolizumab for patients with R/R HL; ongoing evaluation of immune checkpoint inhibitors alone or in combination with other immunotherapies or targeted agents in HL
  • Available and emerging research information with lenalidomide and ibrutinib in newly diagnosed and R/R diffuse large B-cell lymphoma (DLBCL)
  • Recent FDA approval and emerging clinical role of CAR T-cell therapy for patients with DLBCL and other aggressive lymphomas
  • Patient- and/or disease-specific factors guiding the sequence and selection of belinostat, pralatrexate and romidepsin in T-cell lymphoma
  • Clinical implications and prognostic role of minimal residual disease detection in CLL and various lymphoma subtypes

MODULE 7: Breast Cancer 3:10 PM – 4:00 PM

  • Available and emerging data guiding the use of genomic assays to optimize decision-making regarding adjuvant chemotherapy and extended endocrine therapy
  • Factors affecting the selection and sequence of systemic therapy for ER-positive metastatic breast cancer (mBC)
  • FDA approval of ribociclib and integration of CDK4/6 inhibitors into clinical algorithms for patients with ER-positive mBC
  • Recent FDA approval of and Phase III efficacy and safety findings with abemaciclib in ER-positive mBC
  • Results and clinical implications of the Phase III APHINITY trial comparing adjuvant chemotherapy/trastuzumab to chemotherapy/trastuzumab/pertuzumab for HER2-positive early BC
  • Recent FDA approval of neratinib as extended adjuvant therapy: Patient selection and use in clinical practice
  • Ongoing and planned clinical trials incorporating novel HER2-directed therapies in the neoadjuvant and adjuvant settings
  • Published data examining the use of combined endocrine and anti-HER2 blockade for triple-positive mBC
  • Diagnostic and therapeutic implications of the OlympiAD trial documenting a progression-free survival advantage with olaparib versus chemotherapy for patients with germline BRCA mutation-positive, HER2-negative mBC
  • Available data with and ongoing evaluation of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with other systemic agents
  • Other novel agents and approaches under investigation for HER2-positive and triple-negative BC

CE Information

Target Audience:
This live activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals.

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, gastrointestinal, genitourinary, ovarian and select hematologic cancers.
  • Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
  • Recall ongoing trials in breast, lung, gastrointestinal, genitourinary, ovarian and select hematologic cancers, and refer appropriate patients for study participation.
  • Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
  • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
  • Refine or validate existing cancer-specific treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider their potential implications for clinical practice.

Accreditation Statements:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

CME Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Credit Form:
A credit form will be given to each participant at the conclusion of the activity.

CNE Credit Designation Statements:
This educational activity for 6.6 contact hours is provided by Research To Practice.

This activity is awarded 6.6 ANCC pharmacotherapeutic contact hours.

CNE Credit Form:
To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

ONCC/ILNA Certification Information:
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit ResearchToPractice.com/Meetings/YIR2017/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME/CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by Research To Practice, the Accreditation Council for Continuing Medical Education or American Nurses Credentialing Center. Any off-label use as declared by the FDA will be identified.

Educational Support:
This activity is supported by educational grants from AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lexicon Pharmaceuticals Inc, Lilly, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Seattle Genetics, Taiho Oncology Inc, Takeda Oncology and Tesaro Inc.

Research To Practice staff and external reviewers — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.


Westin Boston Waterfront
425 Summer Street
Boston, MA 02210
Hotel phone: (617) 532-4600

Meeting Room: Harbor Ballroom – Conference Level

Room Reservations:
At this time the group housing block is closed. To secure accommodations, please contact the Westin Boston Waterfront directly at (800) 937-8461. A personal credit card will be required to secure accommodations. The hotel will offer their best available rate based on availability. Please be sure to mention you are attending Year in Review 2017.


Thank you for your interest in our Year in Review program. At this time preregistration is closed for this event. However, seats are still available for the program. Onsite registration will be open starting at 7:00 AM (Eastern Time) on Saturday, November 4th. If you are interested in attending, please visit our registration desk located in the Harbor Ballroom foyer on the conference level of the Westin Boston Waterfront hotel (425 Summer Street, Boston, MA 02210).

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.